SELP and peripheral arterial disease: It was previously shown that antiplatelet therapy reduces circulating TF procoagulant activity in patients with peripheral arterial disease.54 To target P-selectin directly 2 monoclonal antibodies crizanlizumab and inclacumab are currently available.